ethyl-5-(2,4-dibenzyloxy-5-isopropylphenyl)-4-iodoisoxazole-3-carboxylate | 1133784-43-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl-5-(2,4-dibenzyloxy-5-isopropylphenyl)-4-iodoisoxazole-3-carboxylate
• 英文别名: ethyl 5-(2,4-bis(benzyloxy)-5-isopropylphenyl)-4-iodoisoxazole-3-carboxylate；ethyl 5-[2,4-bis(phenylmethoxy)-5-propan-2-ylphenyl]-4-iodo-1,2-oxazole-3-carboxylate
• CAS: 1133784-43-6
• 化学式: C₂₉H₂₈INO₅
• 分子量: 597.45
• InChiKey: IYGUTVQSMJPDBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  36
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  70.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl-5-(2,4-dibenzyloxy-5-isopropylphenyl)-4-iodoisoxazole-3-carboxylate 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 氨 、 三溴化硼 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(3-morpholino-prop-1-yn-1-yl)isoxazole-3-carboxamide
  参考文献：
  名称：

  Synthesis and biological evaluation of 3,5-disubstituted-4-alkynylisoxozales as a novel class of HSP90 inhibitors

  摘要：

  A series of 3,5-disubstitute-4-alkynylisoxazole derivatives were designed and synthesized through palladium(II)-copper(I) catalyzed Sonogashira cross-coupling reaction of an alkynyl moiety and an isoxazole scaffold as novel HSP90 inhibitors. The resultant compounds displayed moderate to potent binding affinity to HSP90 proteins, and also demonstrated good cell growth inhibitory activity against various cancer cell lines (A549, K562, MCF-7, DU145 and Hela). Some compounds (18d, 18e, 19a, 19d, 20c and 20q) show similar or better binding affinity towards HSP90a and HSP90b comparing to NVP-AUY922. In addition, compounds 18e, 19a and 20q exhibited potent inhibitory activity against various human cancer cell lines. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.06.009
• 作为产物：
  描述：

  1-(2,4-双(苄氧基)-5-异丙基苯基)乙酮 在 N-碘代丁二酰亚胺 、 ammonium cerium (IV) nitrate 、 盐酸羟胺 、 sodium hydride 作用下， 以 乙醇 、 二氯甲烷 、 甲苯 、 乙腈 、 mineral oil 为溶剂， 反应 2.5h， 生成 ethyl-5-(2,4-dibenzyloxy-5-isopropylphenyl)-4-iodoisoxazole-3-carboxylate
  参考文献：
  名称：

  开发异恶唑作为用于光亲和标记和化学蛋白质组学的天然光交联剂

  摘要：

  异恶唑是药物发现中必不可少的药效团。在这项研究中，我们研究了异恶唑与生物分子的光化学，并将其开发为一种天然嵌入的光交联剂，用于化学蛋白质组学和药物发现。通过这种策略，两种含异恶唑的药物成功应用于化学蛋白质组学平台，以揭示它们的细胞靶点和相互作用。

  DOI：

  10.1002/anie.202209947

文献信息

• HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY
  申请人：Qian Changgeng

  公开号：US20090076006A1

  公开（公告）日：2009-03-19

  The present invention relates to HSP90 inhibitors containing a zinc binding moiety and their use in the treatment of cell proliferative diseases such as cancer. The said derivatives may further act as HDAC inhibitors.

  本发明涉及含有锌结合基团的HSP90抑制剂及其在治疗细胞增殖性疾病如癌症中的应用。所述衍生物还可能作为HDAC抑制剂。
• 5-MEMBERED HETEROCYCLE DERIVATIVES AND MANUFACTURING PROCESS THEREOF
  申请人：Kang Jae-Hoon

  公开号：US20120309750A1

  公开（公告）日：2012-12-06

  Disclosed are a novel 5-membered heterocycle derivatives of Formula I, a tautomer, pharmaceutically acceptable salt, prodrug thereof and a pharmaceutical use thereof. The 5-membered heterocycle derivatives of Formula I, a tautomer, pharmaceutically acceptable salt, prodrug thereof and compositions containing them are useful for treating a tumor.

  本发明涉及一种新型的5-成员杂环衍生物，其化学式为I，其互变异构体，药学上可接受的盐，前药及其制药用途。化合物I的5-成员杂环衍生物，其互变异构体，药学上可接受的盐，前药及其组合物，用于治疗肿瘤。
• RESORCINOL DERIVATIVE AS HSP90 INHIBITOR
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：EP3248968A1

  公开（公告）日：2017-11-29

  The present invention relates to a compound represented by formula (I) of a resorcinol derivative as an HSP90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein HSP90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present invention further provides the compounds and preparation methods for pharmaceutical compositions comprising the compounds, a method for treating diseases, and pharmaceutical compositions comprising the compounds.

  本发明涉及一种由式（I）代表的间苯二酚衍生物作为 HSP90 抑制剂的化合物或其药用盐。本发明中的化合物具有抑制热休克蛋白 HSP90 的活性。因此，本发明中的化合物可用于治疗增殖性疾病，如癌症和神经退行性疾病。本发明进一步提供了本发明化合物和包含本发明化合物的药物组合物的制备方法、治疗疾病的方法和包含本发明化合物的药物组合物。
• Resorcinol derivative as HSP90 inhibitor
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：US10035792B2

  公开（公告）日：2018-07-31

  The present invention relates to a compound represented by formula (I) of a resorcinol derivative as an HSP90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein HSP90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present invention further provides the compounds and preparation methods for pharmaceutical compositions comprising the compounds, a method for treating diseases, and pharmaceutical compositions comprising the compounds.

  本发明涉及一种由式（I）代表的间苯二酚衍生物作为 HSP90 抑制剂的化合物或其药用盐。本发明中的化合物具有抑制热休克蛋白 HSP90 的活性。因此，本发明中的化合物可用于治疗增殖性疾病，如癌症和神经退行性疾病。本发明进一步提供了本发明化合物和包含本发明化合物的药物组合物的制备方法、治疗疾病的方法和包含本发明化合物的药物组合物。
• EP3248968
  申请人：——

  公开号：——

  公开（公告）日：——